Back

Arterial hypertension in the era of obesity bias: the impact of obesity status on pharmacological treatment intensification in patients with diabetes

30 August 2024 (13:00 - 13:40)
Organised by: Logo
Congress Presentation Part of: Risk factors and lifestyle modification in hypertension Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Guilherme Telo

Hospital de Clínicas de Porto Alegre, Porto Alegre (Brazil)

6 More presentations in this session

Presentation thumbnail
Treadmill exercise test as a screening tool in the development of hypertension
Mr T. Kalos (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Effect of DASH vs. Mediterranean diet on metabolic syndrome and cardiometabolic profile in adults with high normal blood pressure or grade 1 hypertension: the DASH-MedDiet randomized controlled trial
Doctor C. Filippou (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Risk factors for cardiometabolic multimorbidity: an analysis of 4 million participants from May Measurement Month 2017-2019
Ms C. Janssen Telders (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
The importance of taste salt sensitivity in the development of kidney damage in patients with high-risked arterial hypertension
Doctor G. Khamidullaeva (Tashkent, UZ)
Abstract Slides Video
Presentation thumbnail
Cumulative effect of lifetime smoking history on arterial stiffness and subclinical atherosclerosis in patients with arterial hypertension
Doctor D. Terentes-Printzios (Athens, GR)
Abstract Slides Video

Access the full session

Session thumbnail
Risk factors and lifestyle modification in hypertension

The Event

Event poster

ESC Congress 2024

30 August 2024 13:00 CET
You may be interested in
thumbnail
Congress Session
Obesity and pre-diabetes: where do we stand today on prevention and treatment?
thumbnail
Congress Session
Challenges of managing obesity in cardiovascular disease
thumbnail
Congress Presentation
Metabolic bariatric surgery as first-line therapy to improve outcomes

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources